BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P. The late adverse events of rituximab therapy--rare but there! Leuk Lymphoma. 2009;50:1083-1095. [PMID: 19399690 DOI: 10.1080/10428190902934944] [Cited by in Crossref: 89] [Cited by in F6Publishing: 80] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 van Stigt AC, Dik WA, Kamphuis LSJ, Smits BM, van Montfrans JM, van Hagen PM, Dalm VASH, IJspeert H. What Works When Treating Granulomatous Disease in Genetically Undefined CVID? A Systematic Review. Front Immunol 2020;11:606389. [PMID: 33391274 DOI: 10.3389/fimmu.2020.606389] [Reference Citation Analysis]
2 Novak J, Mocikova H, Pavlicek P, Gaherova L, Kozak T. Rituximab-induced coagulopathy. Leuk Lymphoma 2012;53:2299-301. [PMID: 22480246 DOI: 10.3109/10428194.2012.682313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
3 Maródi L, Casanova J. Primary immunodeficiencies may reveal potential infectious diseases associated with immune-targeting mAb treatments. Journal of Allergy and Clinical Immunology 2010;126:910-7. [DOI: 10.1016/j.jaci.2010.08.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
4 Saini KS, Azim HA, Cocorocchio E, Vanazzi A, Saini ML, Raviele PR, Pruneri G, Peccatori FA. Rituximab in Hodgkin lymphoma: is the target always a hit? Cancer Treat Rev. 2011;37:385-390. [PMID: 21183282 DOI: 10.1016/j.ctrv.2010.11.005] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
5 Deiß A, Brecht I, Haarmann A, Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2013 update. Expert Rev Neurother 2013;13:313-35. [PMID: 23448220 DOI: 10.1586/ern.13.17] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
6 Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol 2011;86:278-91. [DOI: 10.1002/ajh.21939] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
7 Vikse J, Jonsdottir K, Kvaløy JT, Wildhagen K, Omdal R. Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases. Rheumatol Int 2019;39:1083-90. [PMID: 30923955 DOI: 10.1007/s00296-019-04272-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
8 Chew E, Thursky K, Seymour JF. Very late onset hepatitis-B virus reactivation following rituximab despite lamivudine prophylaxis: the need for continued vigilance. Leukemia & Lymphoma 2014;55:938-9. [DOI: 10.3109/10428194.2013.813502] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
9 Shetty S, Ahmed AR. Preliminary analysis of mortality associated with rituximab use in autoimmune diseases. Autoimmunity 2013;46:487-96. [DOI: 10.3109/08916934.2013.838563] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
10 Kim MJ, Lee GW, Seo JW, Kim HJ, Lim SN, Suh C. Fatal interstitial pneumonitis in a patient with relapsed diffuse large B cell lymphoma following yttrium-90 ibritumomab tiuxetan. Invest New Drugs 2011;29:1098-101. [PMID: 20490611 DOI: 10.1007/s10637-010-9460-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Keene DL, Legare C, Taylor E, Gallivan J, Cawthorn GM, Vu D. Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy. Can J Neurol Sci 2011;38:565-71. [DOI: 10.1017/s0317167100012105] [Cited by in Crossref: 48] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
12 Lee L, Crump M, Khor S, Hoch JS, Luo J, Bremner K, Krahn M, Hodgson DC. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis. Br J Haematol 2012;158:481-8. [DOI: 10.1111/j.1365-2141.2012.09177.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
13 Shepshelovich D, Diker-cohen T, Lahav M. Searching for the leak: Rituximab prophylaxis in acquired angioedema. Am J Hematol 2014;89:928-30. [DOI: 10.1002/ajh.23763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010;5:1394-400. [PMID: 20498238 DOI: 10.2215/CJN.08821209] [Cited by in Crossref: 87] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
15 Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel) 2015;7:305-28. [PMID: 25643241 DOI: 10.3390/cancers7010305] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
16 Maloney C, Blickenstaff N, Kugasia A, Buford LB, Hoffman MD. Vulvovaginal pyoderma gangrenosum in association with rituximab. JAAD Case Rep 2018;4:907-9. [PMID: 30302361 DOI: 10.1016/j.jdcr.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
17 Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia 2018;32:2307-15. [PMID: 30315238 DOI: 10.1038/s41375-018-0285-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
18 Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. Eur J Haematol 2015;94:99-108. [DOI: 10.1111/ejh.12408] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
19 Wedderburn LR, Rider LG. Juvenile dermatomyositis: new developments in pathogenesis, assessment and treatment. Best Pract Res Clin Rheumatol 2009;23:665-78. [PMID: 19853831 DOI: 10.1016/j.berh.2009.07.007] [Cited by in Crossref: 80] [Cited by in F6Publishing: 57] [Article Influence: 6.7] [Reference Citation Analysis]
20 Avilés A, Neri N, Huerta-guzmán J, de Jesús Nambo M. ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2010;10:125-8. [DOI: 10.3816/clml.2010.n.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Reitblat T, Wechsler A, Reitblat O. Rituximab-related late-onset neutropenia in patients with rheumatic diseases: successful re-challenge of the treatment. Am J Case Rep 2015;16:211-4. [PMID: 25855510 DOI: 10.12659/AJCR.892541] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
22 Fluge Ø, Risa K, Lunde S, Alme K, Rekeland IG, Sapkota D, Kristoffersen EK, Sørland K, Bruland O, Dahl O, Mella O. B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. PLoS One 2015;10:e0129898. [PMID: 26132314 DOI: 10.1371/journal.pone.0129898] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
23 Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. European Journal of Internal Medicine 2015;26:659-65. [DOI: 10.1016/j.ejim.2015.07.021] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
24 Maródi L, Casanova JL. Can primary immunodeficiencies help to provide insights into infectious risks of therapeutic antibodies? Nat Rev Immunol 2010;10:299-300. [PMID: 20422788 DOI: 10.1038/nri2764] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
25 Lioté H, Cadranel J, Lioté F. Rituximab-induced pneumonitis: steroid therapy or not? Pediatr Pulmonol 2010;45:412-3; author reply 414-6. [PMID: 20232471 DOI: 10.1002/ppul.21160] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Tomás JF, Montalbán C, De Sevilla AF, Martínez-López J, Díaz N, Canales M, Martínez R, Sánchez-Godoy P, Caballero MD, Peñalver J, Prieto E, Salar A, Burgaleta C, Queizán JA, Bajo R, De Oña R, De La Serna J. Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). Leuk Lymphoma 2011;52:409-16. [PMID: 21275633 DOI: 10.3109/10428194.2010.543717] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
27 Kong F, Wang J, Zheng H, Cai H, Hua J, Li L. Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: a Meta-analysis of Randomized Control Trials. Front Pharmacol 2021;12:652759. [PMID: 34354581 DOI: 10.3389/fphar.2021.652759] [Reference Citation Analysis]
28 Wei W, Zhu Y, Tang J, Xu C, Li J, He S, Zhang Z, Wu P, Luo L, Guo Q, Li F, Ren Y, Yu S, Li R, Li L. Not all bad: Drug-induced interstitial pneumonia in DLBCL patients is potentially fatal but could be linked to better survival. Leuk Res 2021;111:106688. [PMID: 34450501 DOI: 10.1016/j.leukres.2021.106688] [Reference Citation Analysis]
29 Besada E, Koldingsnes W, Nossent JC. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis. Rheumatology (Oxford). 2014;53:1818-1824. [PMID: 24831059 DOI: 10.1093/rheumatology/keu194] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
30 Wolach O, Shpilberg O, Lahav M. Neutropenia after rituximab treatment: new insights on a late complication. Current Opinion in Hematology 2012;19:32-8. [DOI: 10.1097/moh.0b013e32834da987] [Cited by in Crossref: 49] [Cited by in F6Publishing: 10] [Article Influence: 4.9] [Reference Citation Analysis]
31 Chakraborty S, Tarantolo SR, Treves J, Sambol D, Hauke RJ, Batra SK. Progressive Multifocal Leukoencephalopathy in a HIV-Negative Patient with Small Lymphocytic Leukemia following Treatment with Rituximab. Case Rep Oncol 2011;4:136-42. [PMID: 21691572 DOI: 10.1159/000326851] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
32 Seegobin K, Moustafa MA, Gannon N, Keller K, Hastings J, Gupta V, Tun HW, Jiang L. Successful treatment of IgG4-related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab. Clin Case Rep 2021;9:1610-4. [PMID: 33768900 DOI: 10.1002/ccr3.3855] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Forooghian F, MacDonald IM. Rituximab for the Treatment of Autoimmune Retinopathy. Am J Ophthalmol 2017;180:xv-xvi. [PMID: 28662767 DOI: 10.1016/j.ajo.2017.06.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
34 Hirai Y, Ainoda Y, Shoji T, Fujita T, Yoshinaga K, Shiseki M, Mori N, Teramura M, Totsuka K, Motoji T. Disseminated Cryptococcosis in a Non-Hodgkin’s Lymphoma Patient with Late-Onset Neutropenia Following Rituximab-CHOP Chemotherapy: A Case Report and Literature Review. Mycopathologia 2011;172:227-32. [DOI: 10.1007/s11046-011-9423-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
35 Stalika E, Kanellis G, Papalexandri A, Iskas M, Vrakidou E, Demonakou M, Anagnostopoulos A, Stamatopoulos K, Papadaki T. Cytotoxic T cell-mediated gastritis after rituximab treatment for gastric malt lymphoma. Leukemia & Lymphoma 2013;55:702-5. [DOI: 10.3109/10428194.2013.810736] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
36 Jiang X, Mei X, Feng D, Wang X. Prophylaxis and Treatment of Pneumocystis jiroveci Pneumonia in Lymphoma Patients Subjected to Rituximab-Contained Therapy: A Systemic Review and Meta-Analysis. PLoS One 2015;10:e0122171. [PMID: 25909634 DOI: 10.1371/journal.pone.0122171] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
37 Varma P, Falconer J, Aga A, Prince HM, Pianko S. Rituximab-induced Crohn's disease. Scand J Gastroenterol 2017;52:606-8. [PMID: 28129697 DOI: 10.1080/00365521.2017.1280530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
38 Marignani M, Mangone M, Cox MC, Angeletti S, Veggia B, Ferrari A, di Fonzo M, Begini P, Gigante E, Laverde G. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis. 2011;43:139-142. [PMID: 20554488 DOI: 10.1016/j.dld.2010.05.010] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
39 Kristjánsson VB, Lund SH, Gröndal G, Sveinsdóttir SV, Agnarsson HR, Jónasson JG, Björnsson ES. Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. Scand J Gastroenterol 2021;56:46-52. [PMID: 33280485 DOI: 10.1080/00365521.2020.1854847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 García-Cadenas I, Rivera I, Martino R, Esquirol A, Barba P, Novelli S, Orti G, Briones J, Brunet S, Valcarcel D, Sierra J. Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. Bone Marrow Transplant 2017;52:107-13. [PMID: 27595281 DOI: 10.1038/bmt.2016.225] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
41 Marignani M, Fonzo MD, Begini P, Gigante E, Deli I, Pellicelli AM, Gallina S, Santis E, Fave GD, Cox MC. ‘Les liaisons dangereuses’: Hepatitis C, Rituximab and B-cell non-Hodgkin’s lymphomas. World J Gastrointest Pharmacol Ther 2012; 3(2): 21-28 [PMID: 22577616 DOI: 10.4292/wjgpt.v3.i2.21] [Cited by in CrossRef: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Kiefer T, Krahl D, Kohlmann T, Nogai A, Baurmann H, Schüler F, Krüger W, de Wit M, Pink D, Dietz M, Völler H, Buhlert H, Daeschlein G. Does rehabilitation pose a risk to patients suffering from haemato-oncological diseases? Results of a monocentric, retrospective analysis in Germany. Eur J Cancer Care (Engl) 2020;29:e13201. [PMID: 31808982 DOI: 10.1111/ecc.13201] [Reference Citation Analysis]
43 Kato H, Yamamoto K, Taji H, Oki Y, Chihara D, Seto M, Kagami Y, Morishima Y. Interstitial pneumonia after autologous hematopoietic stem cell transplantation in B-cell non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2011;11:483-9. [PMID: 21978956 DOI: 10.1016/j.clml.2011.06.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
44 Price KD, Rao GK. Biological Therapies for Cancer. Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics. Elsevier; 2013. pp. 303-42. [DOI: 10.1016/b978-0-12-394810-6.00013-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Arai Y, Yamashita K, Mizugishi K, Nishikori M, Hishizawa M, Kondo T, Kitano T, Kawabata H, Kadowaki N, Takaori-kondo A. Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. Hematology 2015;20:196-202. [DOI: 10.1179/1607845414y.0000000188] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
46 Cesaro S, Pegoraro A, Tridello G, Calore E, Pillon M, Varotto S, Abate D, Barzon L, Mengoli C, Carli M, Messina C. A Prospective Study on Modulation of Immunosuppression for Epstein-Barr Virus Reactivation in Pediatric Patients Who Underwent Unrelated Hematopoietic Stem-Cell Transplantation. Transplantation 2010;89:1533-40. [DOI: 10.1097/tp.0b013e3181dd6c0a] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
47 Lockmer S, Østenstad B, Hagberg H, Holte H, Johansson A, Wahlin BE, Wader KF, Steen CB, Meyer P, Maisenhølder M, Smedby KE, Brown P, Kimby E. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up. JCO 2018;36:3315-23. [DOI: 10.1200/jco.18.00262] [Cited by in Crossref: 30] [Cited by in F6Publishing: 5] [Article Influence: 7.5] [Reference Citation Analysis]
48 Bugelski PJ, Martin PL. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol 2012;166:823-46. [PMID: 22168282 DOI: 10.1111/j.1476-5381.2011.01811.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
49 Pietrosimone KM, Liu P. Contributions of neutrophils to the adaptive immune response in autoimmune disease. World J Transl Med 2015; 4(3): 60-68 [PMID: 27042404 DOI: 10.5528/wjtm.v4.i3.60] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
50 Selvarajah V, Montano-loza AJ, Czaja AJ. Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs. Aliment Pharmacol Ther 2012;36:691-707. [DOI: 10.1111/apt.12042] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
51 Vikse J, Rygh A, Kaisen K, Omdal R. Life-threatening rituximab-induced pyoderma gangrenosum successfully treated with intravenous immunoglobulin. Scand J Rheumatol 2017;46:413-4. [PMID: 27897446 DOI: 10.1080/03009742.2016.1241298] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
52 Autrel-Moignet A, Lamy T. Autoimmune neutropenia. Presse Med 2014;43:e105-18. [PMID: 24680423 DOI: 10.1016/j.lpm.2014.02.007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
53 Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308-18. [PMID: 20827108 DOI: 10.1097/MD.0b013e3181f2caef] [Cited by in Crossref: 110] [Cited by in F6Publishing: 25] [Article Influence: 9.2] [Reference Citation Analysis]
54 Tesfa D, Palmblad J. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms. Expert Rev Hematol 2011;4:619-25. [PMID: 22077526 DOI: 10.1586/ehm.11.62] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 4.7] [Reference Citation Analysis]
55 Blombery P, Prince HM, Levinson M, Pianko S, Maxwell E, Bhathal P. Rituximab-induced immunodysregulatory ileocolitis in a patient with follicular lymphoma. J Clin Oncol. 2011;29:e110-e112. [PMID: 21098319 DOI: 10.1200/jco.2010.31.8899] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
56 Barba P, Garcia-Cadenas I, Nomdedéu J, Martino R, Gallur L, Valcárcel D. Rituximab treatment may disturb the normal pattern of lymphopoiesis after cord blood SCT. Bone Marrow Transplant 2012;47:458-60. [PMID: 21552304 DOI: 10.1038/bmt.2011.98] [Reference Citation Analysis]
57 Khellaf M, Charles-Nelson A, Fain O, Terriou L, Viallard JF, Cheze S, Graveleau J, Slama B, Audia S, Ebbo M. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients. Blood. 2014;124:3228-3236. [PMID: 25293768 DOI: 10.1182/blood-2014-06-582346] [Cited by in Crossref: 89] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis]
58 Cavagna L, Monti S, Grosso V, Boffini N, Scorletti E, Crepaldi G, Caporali R. The multifaceted aspects of interstitial lung disease in rheumatoid arthritis. Biomed Res Int 2013;2013:759760. [PMID: 24205507 DOI: 10.1155/2013/759760] [Cited by in Crossref: 52] [Cited by in F6Publishing: 41] [Article Influence: 5.8] [Reference Citation Analysis]
59 Pilorge S, Park S, Dreyfus F, Bouscary D, Tamburini J. Rituximab-induced life-threatening coagulopathy occurring in a patient with Waldenström macroglobulinemia treated with fludarabine, cyclophosphamide, and rituximab combination. Leuk Lymphoma 2010;51:2288-90. [PMID: 20929331 DOI: 10.3109/10428194.2010.523127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
60 Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol 2017;32:181-4. [PMID: 27687621 DOI: 10.1007/s00467-016-3498-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
61 Lombardi AM, Berti de Marinis G, Scandellari R, Magalini F, Sansoni P, Ballerini PF, Vettore S, Candeo N, Marson P, De Silvestro G, Fabris F. Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP. Thrombosis Research 2010;126:e154-6. [DOI: 10.1016/j.thromres.2010.02.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
62 Rissanen E, Remes K, Airas L. Severe neutropenia after rituximab-treatment of multiple sclerosis. Mult Scler Relat Disord 2018;20:3-5. [PMID: 29253744 DOI: 10.1016/j.msard.2017.12.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
63 Graf J, Aktas O, Rejdak K, Hartung H. Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs 2019;33:61-78. [DOI: 10.1007/s40259-018-0327-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
64 Pellicelli AM, D’ambrosio C, Dessanti ML, Villani R, Fondacaro L, Miglioresi L, Grillo LR, Andreoli A. Cholestatic hepatitis C after chemotherapy containing rituximab in diffuse large B cell lymphoma. Annals of Hepatology 2015;14:756-61. [DOI: 10.1016/s1665-2681(19)30773-2] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
65 Papalexandri A, Karypidou M, Stalika E, Kotta K, Touloumenidou T, Zerva P, Paleta A, Mallouri D, Batsis I, Sakellari I, Kotsianidis I, Anagnostopoulos A, Hadzidimitriou A, Margaritis D, Stamatopoulos K. Skewing of the T-cell receptor repertoire in patients receiving rituximab after allogeneic hematopoietic cell transplantation: what lies beneath? Leuk Lymphoma 2019;60:1685-92. [PMID: 30652530 DOI: 10.1080/10428194.2018.1543881] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
66 Shahmohammadi S, Sahraian MA, Shahmohammadi A, Doosti R, Zare-Mirzaie A, Naser Moghadasi A. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Mult Scler Relat Disord 2018;22:22-6. [PMID: 29524758 DOI: 10.1016/j.msard.2018.02.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
67 Zhang N, Zhang G, Liu N, Lin W, Ji S, Zheng M, Chen K, Liang X, Li G, Ma Y, Zhu J, Niu T, Li LL, Li J, Wei YQ, Yang SY. A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. Oncotarget 2017;8:111495-507. [PMID: 29340070 DOI: 10.18632/oncotarget.22847] [Reference Citation Analysis]
68 Kim BK, Kang HJ, Hong KT, An HY, Choi JY, Lee JS, Park SS, Shin HY. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation. Transpl Infect Dis 2019;21:e13182. [PMID: 31556214 DOI: 10.1111/tid.13182] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
69 Rezahosseini O, Hanaei S, Hamadani M, Keshavarz-Fathi M, Rezaei N. The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. Int Rev Immunol 2018;37:165-73. [PMID: 29257907 DOI: 10.1080/08830185.2017.1405396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
70 Pettengell R, Aapro M, Brusamolino E, Caballero D, Coiffier B, Pfreundschuh M, Trneny M, Walewski J. Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. Clin Drug Investig 2009;29:491-513. [PMID: 19591512 DOI: 10.2165/00044011-200929080-00001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
71 Wu Y, Jia Y, Xu J, Shuai X, Wu Y. Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-α antagonist and cytokine profiling: a case-report and review of the literature. J Clin Pharm Ther 2013;38:249-53. [PMID: 23506410 DOI: 10.1111/jcpt.12052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
72 Arulkumaran N, Suleman R, Cecconi M, Kiely P, Chua F. Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol 2012;18:39-41. [PMID: 22157278 DOI: 10.1097/RHU.0b013e31823ee5bf] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
73 Giezen TJ, Mantel-teeuwisse AK, ten Berg MJ, Straus SMJM, Leufkens HGM, Solinge WW, Egberts TCG. Rituximab-induced thrombocytopenia: a cohort study. Eur J Haematol 2012;89:256-66. [DOI: 10.1111/j.1600-0609.2012.01808.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
74 Besada E, Nossent JC. CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients. PeerJ 2016;4:e2487. [PMID: 27688979 DOI: 10.7717/peerj.2487] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
75 Rozman S, Sonc M, Novakovic BJ. Late-onset neutropenia following primary treatment of diff use large B-cell lymphoma with rituximab-containing therapy. Leukemia & Lymphoma 2012;53:1945-8. [DOI: 10.3109/10428194.2012.679266] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
76 Sullivan BJ, Kim GJ, Sara G. Treatment dilemma for survivors of rituximab-induced bowel perforation in the setting of post-transplant lymphoproliferative disorder. BMJ Case Rep 2018;11:e226666. [PMID: 30567238 DOI: 10.1136/bcr-2018-226666] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
77 Thomas DA, O'Brien S, Kantarjian HM. Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:949-71, v. [PMID: 19825447 DOI: 10.1016/j.hoc.2009.07.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
78 Czaja AJ. Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis. Dig Dis Sci. 2010;55:2712-2726. [PMID: 20108036 DOI: 10.1007/s10620-009-1122-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
79 Liu Q, Xuan L, Liu H, Huang F, Zhou H, Fan Z, Zhao K, Wu M, Xu L, Zhai X. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol. 2013;88:550-555. [PMID: 23564232 DOI: 10.1002/ajh.23452] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
80 Bennett CM, Tarantino M. Chronic Immune Thrombocytopenia in Children: Epidemiology and Clinical Presentation. Hematology/Oncology Clinics of North America 2009;23:1223-38. [DOI: 10.1016/j.hoc.2009.08.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
81 Aguiar-bujanda D, Blanco-sánchez MJ, Hernández-sosa M, Galván-ruíz S, Hernández-sarmiento S, Saura-grau S, Bohn-sarmiento U. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 2015;15:761-5. [DOI: 10.1016/j.clml.2015.07.635] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
82 Singh AG, Hamarneh IS, Karwal MW, Lentz SR. Durable responses to rituximab in acquired factor VIII deficiency. Thromb Haemost 2017;106:172-4. [DOI: 10.1160/th11-02-0097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
83 Kobayashi Y, Hatta Y, Hojo A, Kura Y, Uchino Y, Takahashi H, Kiso S, Hirabayashi Y, Yagi M, Kodaira H, Kurita D, Tanaka T, Miura K, Iriyama N, Kobayashi S, Sawada U, Sugitani M, Takeuchi J. Long-term follow-up of localized, primary gastric diffuse large B-cell lymphoma treated with rituximab and CHOP. Exp Ther Med 2012;3:304-8. [PMID: 22969886 DOI: 10.3892/etm.2011.387] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
84 Tsuzuki Y, Shiomi R, Ashitani K, Miyaguchi K, Osaki A, Ohgo H, Kim R, Sasaki A, Yamada T, Miyakawa Y, Nakamoto H, Imaeda H. Rituximab-induced Ileocolitis in a Patient with Gastric MALToma: A Case Report and Literature Review. Intern Med 2021;60:731-8. [PMID: 33642561 DOI: 10.2169/internalmedicine.5119-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]